Culture Medium Contains An Albumin Patents (Class 435/388)
  • Patent number: 8945867
    Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
  • Patent number: 8597943
    Abstract: The present invention relates to methods for the cultivation of a population of cells in a serum free cell culture medium, wherein the population of cells has a cell concentration of less than 100 cells/ml, wherein a serum free cell culture medium containing recombinant albumin and recombinant transferrin is used.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: December 3, 2013
    Assignee: CELLCA GmbH
    Inventors: Kolja Hegel, Olaf Kruger, Aziz Cayli
  • Publication number: 20130224784
    Abstract: A method for assessing whether a patient subjected to an antigen-specific Tr1 cell therapy is responding to the treatment, includes: determining in vitro the antigen-specific proliferation of T cells contained in a cell sample from the patient; and comparing the antigen-specific proliferation to a standard reference, thereby determining whether the patient is responding or not to the treatment.
    Type: Application
    Filed: October 7, 2011
    Publication date: August 29, 2013
    Applicant: TXCELL
    Inventors: Arnaud Foussat, Brigitte Quatannens
  • Patent number: 8227207
    Abstract: The invention relates to the production of ovoproducts containing bioactive peptides from the egg white subjected to enzymatic treatment. Said peptides have an inhibiting activity of the angiotensin converting enzyme (ACE inhibiting activity) in vitro and/or anti-hypertensive activity in rats and/or antioxidant activity. Said ovoproducts, complete hydrolyzates, the fractions thereof with low molecular weight or their constituent peptides could be used as therapeutic substances with ACE inhibiting activity and/or anti-hypertensive activity and/or anti-oxidant activity, either as functional food products, food additives or ingredients or pharmaceutical products for the treatment and/or prevention of hypertension in all its forms in humans or animals and for the treatment and/or prevention of any disorder associated with hypertension in humans or animals.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: July 24, 2012
    Assignee: Consejo Superior de Investigaciones Cientifcas
    Inventors: Marta Miguel Castro, Rosina Lopez-Alonso Fandiño, Maria Isidra Recio Sanchez, Maria Mercedes Ramos Gonzalez, Amaya Aleixandre De Artiñano
  • Patent number: 8168429
    Abstract: The present invention provides useful means in an expansion culture system for a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell). Specifically, the present invention provides a composition for expanding a hematopoietic cell (hematopoietic stem cell, hematopoietic progenitor cell) containing recombinant human serum albumin; a serum-free medium for expanding a hematopoietic cell containing a basal medium and recombinant human serum albumin; a method of expanding a hematopoietic cell comprising culturing a hematopoietic cell in a serum-free medium containing recombinant human serum albumin, and a culture of a hematopoietic cell that can be obtained by the expansion method.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: May 1, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Asako Hatsuyama, Kiminari Ito, Tatsutoshi Nakahata
  • Patent number: 7993917
    Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: August 9, 2011
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Samuel K. Martin
  • Patent number: 7989178
    Abstract: A system combining a clonogenic differentiation assay with an instrument-based ATP bioluminescence proliferation assay to produce a standardized colony-forming stem and progenitor cell potency assay is provided.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: August 2, 2011
    Assignee: Hemogenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7883861
    Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: February 8, 2011
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7709258
    Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: May 4, 2010
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7700354
    Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: April 20, 2010
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7666615
    Abstract: The present invention relates generally to assays, methods, and kits that provide reagent mixes and instructions for determining the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: February 23, 2010
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Publication number: 20090028838
    Abstract: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.
    Type: Application
    Filed: August 15, 2008
    Publication date: January 29, 2009
    Applicant: INVITROGEN CORPORATION
    Inventors: John P. Daley, Barbara M. Dadey, William C. Biddle, Michelle G. Wysocki
  • Patent number: 7452721
    Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: November 18, 2008
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Samuel K. Martin
  • Publication number: 20080268538
    Abstract: The present invention provides a device for cell culture. The device comprises a culture zone, a selective sorption zone and culture media transfer means. Culture media is transferred or recirculated from the culture zone through the selective sorption zone which comprises at least one agent reactive with cytotoxic degradation products present in the culture media and back to the culture zone via the culture media transfer means.
    Type: Application
    Filed: September 12, 2005
    Publication date: October 30, 2008
    Inventors: Robert Nordon, Michael R. Doran, Reinhold Deppisch
  • Patent number: 7354730
    Abstract: The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that determine the proliferative status of isolated target cell populations. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The present invention further relates to kits that provide reagent mixes and instructions for high-throughput assays methods for screening compounds that may modulate the proliferative status of a target cell population. The kits of the present invention and methods therein described may be used for determining the proliferative status of any isolated cell line or type. The kits and methods of the present invention address the need for rapid assays that determine the proliferative status of isolated hematopoietic stem and progenitor cells and of subpopulations of differentiated cells thereof.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: April 8, 2008
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7354729
    Abstract: The present invention relates generally to high-throughput assay methods that determine the proliferative status of hematopoietic stem and progenitor cells. The present invention further relates to high-throughput assays for screening compounds that modulate the growth of hematopoietic stem and progenitor cells and for identifying subpopulations thereof that are suitable for transplantation. The assay of the present invention is particularly useful for quality control and monitoring of the growth potential in the stem cell transplant setting and would provide improved control over the reconstitution phase of transplanted cells.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: April 8, 2008
    Assignee: HemoGenix, Inc.
    Inventor: Ivan N. Rich
  • Patent number: 7270990
    Abstract: An improved process for recovery of virus from allantoic fluid of virus-infected chick embryos. Virus associated with granular and fibrous debris in the allantoic fluid can be disassociated from the debris and recovered, thereby increasing viral yield. Dissociation can be achieved by subjecting the virus-debris complex to conditions of increased salt concentrations, e.g., 0.5 M or greater.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: September 18, 2007
    Assignee: Microbix Biosystems, Inc.
    Inventors: Gregory V. Williams, Kenneth Hughes
  • Patent number: 7186557
    Abstract: The invention provides a method of producing neurons from undifferentiated mesenchymal cells (UMC). Also featured by the invention is an isolated neuron produced by this method, compositions containing such neurons, and a method of repairing damaged or defective neural tissues using such compositions.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: March 6, 2007
    Assignee: Isolagen Technologies, Inc.
    Inventor: Olga Marko
  • Patent number: 6994957
    Abstract: The invention provides NAIP nucleic acid and sequences. Also provided are anti-NAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.
    Type: Grant
    Filed: January 17, 1997
    Date of Patent: February 7, 2006
    Assignee: University of Ottawa
    Inventors: Robert G. Korneluk, Alexander E. MacKenzie, Natalie Roy, George Robertson
  • Publication number: 20040214320
    Abstract: The present invention provides a supplement and a culture media useful for culturing mammalian gametes and embryonic tissue. The culture media comprises at least one of recombinant human albumin, fermented hyaluronan, and citrate. Because the constituents are produced from non-conventional sources, the culture medium is free from contaminants such as viruses, prions and endotoxins. Additionally, because the medium is completely defined, the medium is not subject to variations which can impair the development of mammalian cells and prevent meaningful comparisons of empirical studies.
    Type: Application
    Filed: January 26, 2004
    Publication date: October 28, 2004
    Applicant: Vitrolife, Inc,
    Inventors: David K. Gardner, Michelle T. Lane
  • Patent number: 6733746
    Abstract: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: May 11, 2004
    Assignee: Invitrogen Corporation
    Inventors: John P. Daley, Barbara M. Dadey, William C. Biddle, Michelle G. Wysocki
  • Publication number: 20030170887
    Abstract: A novel cell culture medium suitable for primary culture of insect cells, an insect-derived water-soluble chitin, and a process of preparing an insect culture cell line in a short period of time by using the insect primary culture medium and the insect-derived water-soluble chitin. The insect cell primary culture medium comprises lactalbumin hydrolysate, yeastolate, and tryptose phosphate broth as protein extracts, and polyvinylpyrrolidone as a viscosity-supplementing agent. The insect-derived water-soluble chitin is subjected to deacetylation as the sole chemical modification.
    Type: Application
    Filed: March 6, 2002
    Publication date: September 11, 2003
    Applicant: National Institute of Agrobiological Sciences
    Inventors: Shigeo Imanishi, Atsunobu Haga, Jun Mitsuhashi
  • Patent number: 6617161
    Abstract: A chemically defined-serum free growth medium for the in vitro and ex vivo of cells and cell lines. The medium consists of about a one to one ratio (v/v) of two basal growth media containing &agr;-ketoglutarate, insulin, transferrin, selenium, bovine serum albumin, linoleic acid, ceruloplasmin, cholesterol, phosphatidyl-ethanolamine, &agr;-tocopherol acid succinate, reduced glutathione, taurine, triiodothyronine, hydrocortisone, parathyroid hormone, L-ascorbic acid 2-sulfate, &bgr;-glycerophosphate, PDGF, EGF and FGF. Chondrocytes, when cultured in this medium in the presence of a cartilage derived morphogenetic protein or bone morphogenetic protein, retain their cartilaginous phenotype.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: September 9, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank P. Luyten, Ludwig Erlacher
  • Publication number: 20020155603
    Abstract: A chemically defined mammalian cell culture medium is provided that supports maintenance and long term clonal growth of mammalian hepatocytes and other cells.
    Type: Application
    Filed: February 12, 2002
    Publication date: October 24, 2002
    Applicant: University of Pittsburgh
    Inventor: Geoffrey D. Block
  • Patent number: 6413772
    Abstract: A chemically defined mammalian cell culture medium is provided that supports maintenance and long term clonal growth of mammalian hepatocytes and other cells.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: July 2, 2002
    Assignee: University of Pittsburgh
    Inventor: Geoffrey D. Block
  • Patent number: 6372493
    Abstract: Methods are provided for the establishment and maintenance in long term culture of hormone secreting cells. Cells are derived from tumorous or non-tumorous animal or human tissues, including ovary, endometrium, trophoblast, pituitary, thyroid, and pancreas. The cells secrete into the culture medium hormones such as estrogens, progestins, follicle-stimulating hormone, luteinizing hormone, human chorionic gonadotrophin, thyroxin, glucagon, and insulin, depending on the tissue of origin of individual cell cultures. Contact with an appropriate secretogogue causes the cells to respond with increased hormone secretion. For instance, ovarian follicular cells respond to follicle-stimulating hormone with increased estrogen and progesterone secretion. Pancreatic cells respond to elevated glucose with increased insulin secretion. The cells proliferate in in vitro for up to one year or longer, during which time they retain their hormone-secretion profile.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: April 16, 2002
    Assignee: Pacific Biomedical Research, Inc. [Cell Mart, Inc.]
    Inventor: Ann Janice Brothers
  • Publication number: 20020042132
    Abstract: The present invention provides a supplement and a culture media useful for culturing mammalian gametes and embryonic tissue. The culture media comprises at least one of recombinant human albumin, fermented hyaluronan, and citrate. Because the constituents are produced from non-conventional sources, the culture medium is free from contaminants such as viruses, prions and endotoxins. Additionally, because the medium is completely defined, the medium is not subject to variations which can impair the development of mammalian cells and prevent meaningful comparisons of empirical studies.
    Type: Application
    Filed: June 8, 2001
    Publication date: April 11, 2002
    Inventors: David K. Gardner, Michelle T. Lane
  • Publication number: 20010033835
    Abstract: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.
    Type: Application
    Filed: January 31, 1997
    Publication date: October 25, 2001
    Inventors: JOHN P. DALEY, BARBARA M. DADEY, WILLIAM C. BIDDLE, MICHELLE G. WYSOCKI
  • Patent number: 6274305
    Abstract: A method of testing cancer cells is described. Assays are provided for determining the potential for inhibiting cancer cells proliferation using albumin-derived peptides. The methods of the present invention allow for drug screening as well as for evaluation of biopsied tumors.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: August 14, 2001
    Assignee: Tufts University
    Inventors: Carlos Sonnenschein, Ana M. Soto
  • Patent number: 6043092
    Abstract: A chemically defined mammalian cell culture medium is provided that supports maintenance and long term clonal growth of mammalian hepatocytes and other cells.
    Type: Grant
    Filed: March 18, 1996
    Date of Patent: March 28, 2000
    Assignee: University of Pittsburgh
    Inventor: Geoffrey D. Block
  • Patent number: 5908782
    Abstract: A composition and method for maintaining the viability of human mesenchymal precursor cells in a serum-free environment which composition includes (1) a minimum essential medium; (2) serum albumin; (3) an iron source; (4) insulin or an insulin-like growth factor; and (5) at least one amino acid selected from the group consisting of glutamine, arginine and and cysteine, and is free of serum. Also, a composition and method for culture expanding human mesenchymal precursor cells in a serum-free environment. This composition further includes a mitogen, paricularly a serotonergic agonist. The cells are preferably isolated human mesenchymal stem cells.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 1, 1999
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Daniel R. Marshak, James J. Holecek
  • Patent number: 5780301
    Abstract: Disclosed is a synthetic medium with PDGF, vitronectin, IL-1.beta. and BSA added to Eagle's minimum essential medium or medium with transferrin, insulin, progesterone and putrescine further added thereto. When cultivating the postnatal central neurons using the inventive medium, there are effects such that good attachment to substrate, extension of neuritic processes and maintenance of survival are achieved, that more stable sure cultivation becomes possible as well over the astrocyte-conditioned medium used hitherto, and the like.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: July 14, 1998
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Saito, Hiroshi Katsuki, Fumio Kawahara